STUDY PERIOD
Start date: September 21, 2022
End date: January 2023
STUDY INFORMATION
Indication: The expected benefit to subjects being treated with Xxxx is a rapid decrease in SARS-CoV-2 viral load within a short treatment period.
Frequency of Visit:
Screening Visit: 1
In Person Visit: 8
STUDY CRITERIA
Age: 18 to 64 years old
Gender: Both
